drug safety

A doctor with a graphic representation of the lungs

Biotech

Pliant ends lung disease program over rise in adverse events

Pliant has terminated its IPF program after digging into the increased rate of adverse events from a 2b/3 trial of its lead candidate bexotegrast.

James Waldron Jun 30, 2025 4:49am

FDA

Fierce Pharma

FDA investigates 2 deaths after Sarepta Duchenne gene therapy

Jun 25, 2025 10:26am

Fierce Pharma

2nd patient dies after Sarepta's DMD gene therapy Elevidys

Jun 16, 2025 10:58am

Magnifying glass with pills on blue

FDA's CMO steps down

Apr 2, 2025 10:02am

cancelled flights

Pliant terminates lung disease trial due to adverse events

Mar 3, 2025 11:30am

Gene editing CRISPR gene therapy

Neurogene acts as gene therapy puts person in critical condition

Nov 18, 2024 8:33am